09.02.10
NextPharma has expanded its microbiology facilities at its site in Göttingen, Germany. The expansion includes the addition of three new labs equipped with modern air ventilation, laminar-flow benches and temperature-controlled incubators linked to a computerized monitoring system designed to ensure a constant temperature.
The new labs will be used to develop and validate microbiological methods as well as to test non-sterile pharmaceutical products, medical devices and cosmetics for microbial purity and preservative efficiency. Additionally, the new labs can work sequentially to process samples enabling a high throughput of testing. The Göttingen microbiology department now has the capacity to test 40,000 samples per year. Microbiological testing of sterile products will continue to be undertaken at NextPharma’s Belgium facility.
Sean Marett, managing director, NextPharma Technologies, Product Development Services, said, “We are delighted to expand our microbiology department in Göttingen, which will enable us to grow our Product Development Services offering in this field of expertise. We look forward to working with new and existing customers in the pharmaceutical, medical device and cosmetics markets.”
The new labs will be used to develop and validate microbiological methods as well as to test non-sterile pharmaceutical products, medical devices and cosmetics for microbial purity and preservative efficiency. Additionally, the new labs can work sequentially to process samples enabling a high throughput of testing. The Göttingen microbiology department now has the capacity to test 40,000 samples per year. Microbiological testing of sterile products will continue to be undertaken at NextPharma’s Belgium facility.
Sean Marett, managing director, NextPharma Technologies, Product Development Services, said, “We are delighted to expand our microbiology department in Göttingen, which will enable us to grow our Product Development Services offering in this field of expertise. We look forward to working with new and existing customers in the pharmaceutical, medical device and cosmetics markets.”